Dr. Reddys Laboratories Ltd.

Dr. Reddys Laboratories is currently trading at Rs. 3538.00, up by 50.55 points or 1.45% from its previous closing of Rs. 3487.45 on the BSE.

The scrip opened at Rs. 3531.00 and has touched a high and low of Rs. 3564.95 and Rs. 3531.00 respectively. So far 6978 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 5 has touched a 52 week high of Rs. 3662.00 on 01-Dec-2014 and a 52 week low of Rs. 2250.00 on 19-May-2014.

Last one week high and low of the scrip stood at Rs. 3570.00 and Rs. 3363.15 respectively. The current market cap of the company is Rs. 60331.97 crore.

The promoters holding in the company stood at 25.49% while Institutions and Non-Institutions held 44.19% and 12.91% respectively.

Dr Reddy’s Laboratories has entered into a definitive agreement to acquire a select portfolio of the established products business of UCB, in the territories of India, Nepal, Sri Lanka and Maldives. The acquired business is being sold on a slump sale basis. The transaction includes around 350 employees engaged in operations of the India Business.

The revenue of the acquired business is around Rs 150 crore for calendar year 2014. The acquisition of UCB’s existing brand equity in the areas of Dermatology, Respiratory and Pediatrics diseases will further expand Dr Reddy’s therapy footprint into these fast growing areas.

Dr. Reddy’s is an integrated global pharmaceutical company, committed to providing affordable and innovative medicines for healthier lives. Through its three businesses - Pharmaceutical Services and Active Ingredients, Global Generics and Proprietary Products - the company offers a portfolio of products and services including APIs, custom pharmaceutical services, generics, bio-similars, differentiated formulations and NCEs.